{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:55Z","timestamp":1787026615931,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Tuberculosis (TB) remains among the leading infectious causes of death. Due to the limited number of antimicrobials in the TB drug discovery pipeline, interest has developed in host-directed approaches to improve TB treatment outcomes. C-C motif chemokine-like receptor 2 (CCRL2) is a unique seven-transmembrane domain receptor that is upregulated by inflammatory signals and mediates leucocyte migration. However, little is known about its role in TB infection. Here, we show that\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    (Mtb) infection increases CCRL2 protein expression in macrophages\n                    <jats:italic>in vitro<\/jats:italic>\n                    and alveolar macrophages (AMs), dendritic cells (DCs) and neutrophils in mouse lungs. To target selectively CCRL2-expressing cells\n                    <jats:italic>in vivo<\/jats:italic>\n                    , we developed a novel mouse anti-CCRL2 antibody-drug conjugate (ADC) linked with the cytotoxic drug SG3249. We tested its adjunctive therapeutic efficacy against TB when combined with the first-line regimen for drug-susceptible TB (isoniazid, rifampin, pyrazinamide, ethambutol; RHZE). The anti-CCRL2 ADC treatment potentiated RHZE efficacy in Mtb-infected mice and decreased gross lung inflammation. CCRL2 expression in lung DCs and AMs was lower in mice receiving anti-CCRL2 ADC treatment+RHZE compared to those receiving RHZE alone or the control group, although the total innate cell populations did not differ across treatment groups. Interestingly, neutrophils were completely absent in the anti-CCRL2 ADC treatment + RHZE group, unlike in the other treatment groups. IFN-\u03b3+-and IL17-\u03b1+-T-cell responses, which are associated with optimal TB control, were also elevated in the anti-CCRL2 ADC treatment + RHZE group. Our findings suggest that CCRL2-targeting approaches may improve TB treatment outcomes, possibly through selective killing of Mtb-infected innate immune cells.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1501329","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T01:28:06Z","timestamp":1742434086000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting CCRL2 enhances therapeutic outcomes in a tuberculosis mouse model"],"prefix":"10.3389","volume":"16","author":[{"given":"Tianyin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darla","family":"Quijada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Ahmedna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie Ruelas","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour Sabiha","family":"Naji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J David","family":"Peske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros C.","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Karantanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Karanika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"B1","unstructured":"Tuberculosis\n          \n          2023"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1086\/587904","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research","volume":"197","author":"Fauci","year":"2008","journal-title":"J Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00680","article-title":"Antibiotic treatment shapes the antigenic environment during chronic TB infection, offering novel targets for therapeutic vaccination","volume":"11","author":"Chuang","year":"2020","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","article-title":"Therapeutic host-directed strategies to improve outcome in tuberculosis","volume":"13","author":"Young","year":"2020","journal-title":"Mucosal Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.9.5322-5327.2002","article-title":"Neutrophil-mediated mycobacteriocidal immunity in the lung during Mycobacterium bovis BCG infection in C57BL\/6 mice","volume":"70","author":"Fulton","year":"2002","journal-title":"Infect Immun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.3.1744-1753.2005","article-title":"Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice","volume":"73","author":"Eruslanov","year":"2005","journal-title":"Infect Immun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.88","article-title":"Innate immunity in tuberculosis: host defense vs pathogen evasion","volume":"14","author":"Liu","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00075198-200102000-00001","article-title":"Neutrophil activation and acute lung injury","volume":"7","author":"Lee","year":"2001","journal-title":"Curr Opin Crit Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-013-0388-2","article-title":"Macrophages in tuberculosis: friend or foe","volume":"35","author":"Guirado","year":"2013","journal-title":"Semin Immunopathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4161\/viru.22586","article-title":"The role of dendritic cells in Mycobacterium tuberculosis infection","volume":"3","author":"Mihret","year":"2012","journal-title":"Virulence"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207202","article-title":"Mycobacterial glycolipid Di-O-acyl trehalose promotes a tolerogenic profile in dendritic cells","volume":"13","author":"Magallanes-Puebla","year":"2018","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00268-X","article-title":"Release of neutrophil elastase and its role in tissue injury in acute inflammation: effect of the elastase inhibitor, FR134043","volume":"374","author":"Fujie","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.615031","article-title":"Molecular basis for CCRL2 regulation of leukocyte migration","volume":"8","author":"Schioppa","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-777680","article-title":"The atypical receptor CCRL2 is required for CXCR2-dependent neutrophil recruitment and tissue damage","volume":"130","author":"Del Prete","year":"2017","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl8952","article-title":"The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia","volume":"8","author":"Karantanos","year":"2022","journal-title":"Sci Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281444","article-title":"CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine","volume":"108","author":"Karantanos","year":"2023","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","first-page":"22072","DOI":"10.1038\/s41598-020-78793-2","article-title":"Whole blood mRNA expression-based targets to discriminate active tuberculosis from latent infection and other pulmonary diseases","volume":"10","author":"Petrilli","year":"2020","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10753-019-01132-9","article-title":"Mycobacterium tuberculosis heat-shock protein 16.3 induces macrophage M2 polarization through CCRL2\/CX3CR1","volume":"43","author":"Zhang","year":"2020","journal-title":"Inflammation"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.972266","article-title":"An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis","volume":"13","author":"Karanika","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd3595","article-title":"TCR \u03b2 chain-directed bispecific antibodies for the treatment of T cell cancers","volume":"13","author":"Paul","year":"2021","journal-title":"Sci Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07233-2","article-title":"TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers","volume":"628","author":"Nichakawade","year":"2024","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200904-0611OC","article-title":"Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis","volume":"180","author":"Williams","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ni1449","article-title":"IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge","volume":"8","author":"Khader","year":"2007","journal-title":"Nat Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev.immunol.021908.132703","article-title":"Cell-mediated immune responses in tuberculosis","volume":"27","author":"Cooper","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","article-title":"Prevention of tuberculosis in macaques after intravenous BCG immunization","volume":"577","author":"Darrah","year":"2020","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.03.611055","article-title":"Therapeutic DNA vaccine targeting mycobacterium tuberculosis persisters shortens curative tuberculosis treatment","author":"Karanika","year":"2024","journal-title":"bioRxiv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.10.2497","article-title":"Chemokine receptor homo- or heterodimerization activates distinct signaling pathways","volume":"20","author":"Mellado","year":"2001","journal-title":"EMBO J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.2MR1217-503R","article-title":"Remodeling our concept of chemokine receptor function: From monomers to oligomers","volume":"104","author":"Mart\u00ednez-Mu\u00f1oz","year":"2018","journal-title":"J Leukocyte Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01621","article-title":"Absence of the non-signalling chemerin receptor CCRL2 exacerbates acute inflammatory responses in vivo","volume":"8","author":"Regan-Komito","year":"2017","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.20275","article-title":"Up-regulated expression and activation of the orphan chemokine receptor, CCRL2, in rheumatoid arthritis","volume":"50","author":"Galligan","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00708.x","article-title":"Dendritic cells and the regulation of the allergic immune response","volume":"60","author":"Lambrecht","year":"2005","journal-title":"Allergy"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-259903","article-title":"Nonredundant role of CCRL2 in lung dendritic cell trafficking","volume":"116","author":"Otero","year":"2010","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer\u2013containing antibody drug conjugate targeting CD19-expressing Malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102871","article-title":"Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells","volume":"189","author":"Monnier","year":"2012","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.08.009","article-title":"Ccrl2 deficiency deteriorates obesity and insulin resistance through increasing adipose tissue macrophages infiltration","volume":"9","author":"Xu","year":"2022","journal-title":"Genes Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00140913","article-title":"Neutrophilia independently predicts death in tuberculosis","volume":"42","author":"Lowe","year":"2013","journal-title":"Eur Respir J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03147","article-title":"Imbalance of NET and alpha-1-antitrypsin in tuberculosis patients is related with hyper inflammation and severe lung tissue damage","volume":"9","author":"De Melo","year":"2018","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1501329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T01:28:11Z","timestamp":1742434091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1501329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1501329"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1501329","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.23.614576","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"article-number":"1501329"}}